Published in Oncoimmunology on February 10, 2017
Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (2005) 23.44
Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med (1991) 19.46
Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer (2008) 15.20
Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov (2007) 11.46
Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature (2007) 9.09
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell (2004) 8.78
Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature (2006) 7.01
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature (2006) 6.56
Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol (2005) 6.44
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med (2013) 5.82
Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev (2011) 5.64
Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol (2002) 5.04
The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol (2005) 4.54
Specific EGF repeats of Notch mediate interactions with Delta and Serrate: implications for Notch as a multifunctional receptor. Cell (1991) 4.37
Pref-1, a protein containing EGF-like repeats, inhibits adipocyte differentiation. Cell (1993) 4.19
In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor. J Exp Med (2007) 2.89
Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res (2008) 2.84
Random migration precedes stable target cell interactions of tumor-infiltrating T cells. J Exp Med (2006) 2.43
Notch signaling in blood vessels: who is talking to whom about what? Circ Res (2007) 2.00
Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization. Immunity (2006) 1.95
Impact of epitope escape on PD-1 expression and CD8 T-cell exhaustion during chronic infection. J Virol (2009) 1.77
Tim3 binding to galectin-9 stimulates antimicrobial immunity. J Exp Med (2010) 1.66
HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses. Proc Natl Acad Sci U S A (2009) 1.59
dlk acts as a negative regulator of Notch1 activation through interactions with specific EGF-like repeats. Exp Cell Res (2004) 1.57
Anti-cancer therapies targeting the tumor stroma. Cancer Immunol Immunother (2007) 1.49
Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int J Cancer (2011) 1.39
Localization of the delta-like-1-binding site in human Notch-1 and its modulation by calcium affinity. J Biol Chem (2008) 1.34
IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer (2015) 1.32
Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer (2016) 1.31
Therapeutic cancer vaccines. J Clin Invest (2015) 1.23
Hypoxia-regulated delta-like 1 homologue enhances cancer cell stemness and tumorigenicity. Cancer Res (2009) 1.23
Regulation of angiogenesis by homotypic and heterotypic notch signalling in endothelial cells and pericytes: from basic research to potential therapies. Angiogenesis (2008) 1.18
Endothelial Wnt/β-catenin signaling inhibits glioma angiogenesis and normalizes tumor blood vessels by inducing PDGF-B expression. J Exp Med (2012) 1.12
Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment. Immunology (2014) 1.10
Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium. BMC Genomics (2008) 1.03
Anti-angiogenesis: making the tumor vulnerable to the immune system. Cancer Immunol Immunother (2008) 1.01
Induction of Dlk1 by PTTG1 inhibits adipocyte differentiation and correlates with malignant transformation. Mol Biol Cell (2009) 0.98
The EGF-like proteins DLK1 and DLK2 function as inhibitory non-canonical ligands of NOTCH1 receptor that modulate each other's activities. Biochim Biophys Acta (2011) 0.98
Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature. J Clin Invest (2014) 0.96
DLK1 as a potential target against cancer stem/progenitor cells of hepatocellular carcinoma. Mol Cancer Ther (2012) 0.96
Transcriptional regulation by hypoxia inducible factors. Crit Rev Biochem Mol Biol (2013) 0.94
HIF-1α depletion results in SP1-mediated cell cycle disruption and alters the cellular response to chemotherapeutic drugs. Cell Cycle (2011) 0.93
Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model. Melanoma Res (2012) 0.92
DLK1, delta-like 1 homolog (Drosophila), regulates tumor cell differentiation in vivo. Cancer Lett (2011) 0.91
Vaccination approach to anti-angiogenic treatment of cancer. Biochim Biophys Acta (2015) 0.88
Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice. J Immunol (2012) 0.87
The novel gene EGFL9/Dlk2, highly homologous to Dlk1, functions as a modulator of adipogenesis. J Mol Biol (2006) 0.86
Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma. Oncoimmunology (2014) 0.82
Transcription factor Klf4, induced in the lung by oxygen at birth, regulates perinatal fibroblast and myofibroblast differentiation. PLoS One (2013) 0.79
DLK1: a novel target for immunotherapeutic remodeling of the tumor blood vasculature. Mol Ther (2013) 0.78
Evidence of non-canonical NOTCH signaling: Delta-like 1 homolog (DLK1) directly interacts with the NOTCH1 receptor in mammals. Cell Signal (2016) 0.77
Characterization of a proximal Sp1 response element in the mouse Dlk2 gene promoter. BMC Mol Biol (2011) 0.77
DLK2 is a transcriptional target of KLF4 in the early stages of adipogenesis. J Mol Biol (2012) 0.76